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Background: Influenza neuraminidase (NA) is an important target for antiviral inhibitors since its active site is highly
conserved such that inhibitors can be cross-reactive against multiple types and subtypes of influenza. Here, we
discuss the crystal structure of neuraminidase subtype N9 complexed with a new benzoic acid based inhibitor (2)
that was designed to add contacts by overpacking one side of the active site pocket. Inhibitor 2 uses benzoic acid
to mimic the pyranose ring, a bis-(hydroxymethyl)-substituted 2-pyrrolidinone ring in place of the N-acetyl group of
the sialic acid, and a branched aliphatic structure to fill the sialic acid C6 subsite.
Results: Inhibitor 2 {4-[2,2-bis(hydroxymethyl)-5-oxo-pyrrolidin-1-yl]-3-[(dipropylamino)methyl)]benzoic acid} was
soaked into crystals of neuraminidase of A/tern/Australia/G70c/75 (N9), and the structure refined with 1.55 Å X-ray
data. The benzene ring of the inhibitor tilted 8.9° compared to the previous compound (1), and the number of
contacts, including hydrogen bonds, increased. However, the IC50 for compound 2 remained in the low micromolar
range, likely because one propyl group was disordered. In this high-resolution structure of NA isolated from virus
grown in chicken eggs, we found electron density for additional sugar units on the N-linked glycans compared to
previous neuraminidase structures. In particular, seven mannoses and two N-acetylglucosamines are visible in the
glycan attached to Asn200. This long, branched high-mannose glycan makes significant contacts with the
neighboring subunit.
Conclusions: We designed inhibitor 2 with an extended substituent at C4-corresponding to C6 of sialic acid-to
increase the contact surface in the C6-subsite and to force the benzene ring to tilt to maximize these interactions
while retaining the interactions of the carboxylate and the pyrolidinone substituents. The crystal structure at 1.55 Å
showed that we partially succeeded in that the ring in 2 is tilted relative to 1 and the number of contacts
increased, but one hydrophobic branch makes no contacts, perhaps explaining why the IC50 did not decrease.
Future design efforts will include branches of unequal length so that both branches may be accommodated in the
C6-subsite without conformational disorder. The high-mannose glycan attached to Asn200 makes several inter-
subunit contacts and appears to stabilize the tetramer.
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Figure 1 NA inhibitors. A, Zanamivir; B, oseltamivir; C, Inhibitor 1
(compound 14 of Brouillette et al. [17]); D, Inhibitor 2; E, The NA
subsites that surround the transition state analog 2-deoxy-2-
dehydro-N-acetylneuraminic acid (DANA). Note that in the benzoic
acid series, subsite 6 is adjacent to C4 of the benzene ring. Figure
made with PDB ID: 1NNB.
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Influenza A viruses display two membrane-anchored glyco-
proteins, hemagglutinin (HA) and neuraminidase (NA).
HA mediates attachment of the virus to sialic acid recep-
tors on host cells to initiate virus infection. After virus rep-
lication, NA removes sialic acid residues from viral and
cellular glycoproteins to facilitate virus release and allow
spread of infection to new cells. In the absence of NA activ-
ity, the progeny virions aggregate and infection ends [1,2].
The distinct antigenic properties of HA and NA from dif-
ferent viruses are used to classify influenza type A into sub-
types—16 for HA and 9 for NA. H1N1 (1918), H2N2
(1957) and H3N2 (1968) caused the major influenza pan-
demics of the 20th century. Evidence that the new HA and
sometimes NA genes originated in wild birds before
appearing in humans has raised concerns about the recent
spread of highly pathogenic avian H5N1 viruses. These
viruses have the potential to gain transmissibility among
humans and thereby devastate immunologically naïve
human populations [3]. Type B viruses are not carried by
birds and are not divided into antigenic subtypes, but since
the mid-1980s, two lineages, B/Victoria and B/Yamagata,
have been evolving concurrently in humans [4].
NA is a good target for structure-based enzyme inhibitor
design because its well-characterized active site is conserved
across all influenza A and B viruses [5]. The 11 amino acids
in the active site that interact with sialic acid remain un-
changed amidst extensive genetic variation in the rest of the
sequence [6-8]; for an alignment, see [9]. Structure-based
drug design led to the successful antiviral drugs zanamivir
(GG167) [10] and oseltamivir (GS4071) [11] that are effect-
ive against different types and subtypes of influenza. Zanami-
vir is based on a transition state analogue of sialic acid while
oseltamivir replaces sialic acid's pyranose ring with a cyclo-
hexene scaffold (Figure 1). The high potency and oral activity
of oseltamivir encourages the use of alternative scaffolds to
replace the sugar ring of sialic acid [12-14]. Benzene ring
scaffolds minimize the number of chiral centers, potentially
simplifying the chemical synthesis and reducing associated
expenses [15-18]. The challenge is to configure substituents
on the ring to optimize the interactions with the active site.
The direct contacts with sialic acid are conserved in all
influenza NAs, but the subsites that surround the sialic
acid—named according to the ring atoms of sialic acid
(Figure 1E)—show differences in size and shape between
strains and sometimes account for large differences in po-
tency between N1, N2 and B NAs [17,19]. In addition, inhi-
bitors with a hydrophobic side chain often show differences
in potency between the two structural groups of type A NA:
group 1 (subtypes N1, N4, N5 and N8) and group 2 (sub-
types N2, N3, N6, N7, and N9) [20].
X-ray structures of several simple benzoic acid deriva-
tives bound to influenza B NA show that these inhibitors
bind to the active site in the same orientation as sialicacid [15,16]. The derivatives' common carboxylate substi-
tution at the C2 position maintains the native interaction
with the arginine triad (Arg292, Arg118, and Arg371 in
N2 numbering), and the N-acetyl substitution at the C5
subsite maintains the native interaction with Arg152.
In addition, using a benzene ring scaffold, hydrophobic
groups of varying lengths fit into the glycerol binding site
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ing of the aliphatic chain have been modified to improve
inhibition, but benzoic acids from this structural class have
yet to match the inhibitory activities observed for zanami-
vir and oseltamivir. It is likely that this results from the
lack of a basic group (aliphatic amine or guanidine) in the
C4 subsite, which forms an important salt bridge with
inhibitors in clinical use.
One of the best compounds from the existing benzoic
acid series, inhibitor 1, (Figure 1C) lacks the C4 subsite
substituent yet exhibited moderately potent (low to mid
nM) activity against NAs of the N2 and N9 subtypes of in-
fluenza A virus, with less inhibitory activity against influ-
enza B virus NA, as observed for other compounds with a
similar hydrophobic substituent on the benzene ring [18].
We are trying to broaden the specificity of the benzoic
acids against influenza viruses of different subtypes and to
increase potency. The best way to accomplish this goal is
likely by adding a basic substituent to form a salt bridge in
the C4 subsite. However, attempts to design substituents on
the benzene ring that occupy both the negatively charged C4
subsite and the glycerol binding site (C6 subsite) of sialic
acid have been difficult because the two subsites are offset
from the plane of the benzene ring. The results of molecular
modeling studies using FlexX [22] suggested that a different
“tilt” of the benzene ring may be needed, and one way to
alter the tilt may be to change the size of the hydrophobic
substituent, such that an increase or a decrease in steric
crowding reorients the benzene ring in the binding site.
The inhibitor studied here, compound 2, like compound 1,
contains no chiral centers but has a longer hydrophobic sub-
stituent consisting of a 3-heptyl (instead of 3-pentyl) group
positioned one atom further from the benzene ring
(Figure 1D). Enzyme inhibition assays indicate that the affin-
ity of 2 is in the low micromolar range for type A NAs but,
compared to 1, lower for type B NA (Table 1) [12,17]. We
have determined the crystal structure of 2 in complex with a
type A N9 NA to a resolution of 1.55 Å, and we discuss it in
terms of the successful reorientation of the benzene ring and
the lack of improvement in binding affinity. The structure of
the complex suggests routes to design inhibitors that might
show improved affinity.Table 1 IC50 values of the inhibitor 2 compared with
compound 1
Inhibitor NA IC50 (μM)
1 [17] A/Udorn/72 NA (N2) 0.49
A/tern/Australia/G70c NA (N9) 4.4
B/Lee/40 NA 271
2 [23] H3N2 2
H1N1 20
A/tern/Australia/G70c NA (N9) 9.1 ± 2.2
B/Lee/40 NA 180Results and discussion
Overall structure
N9 NA crystals that had been soaked with inhibitor 2
showed similar unit cell dimensions and space group
symmetry as low temperature crystal structures of other
N9-inhibitor complexes and the uncomplexed mutant
R292K (Protein Data Bank identifier [PDB ID] 2QWA)
[24]. The available uncomplexed native structures (PDB
ID, 1NNA and 7NN9) were determined at room
temperature and were not as suitable for direct compari-
son with our low temperature data, so we judged the
crystal structure of the uncomplexed mutant R292K to
be a less biased starting model for molecular replace-
ment. Inhibitor 2 bound to the active site with nearly full
occupancy (refined occupancy factor of 0.68) and did not
bind to additional sites such as the second sialic acid
binding site [25,26] (PDB ID, 2C4A).
Inhibitor–N9 interactions
The X-ray data were of high quality and the structure of 2
complexed with N9 NA was refined with 1.55 Å X-ray data.
The final model had good geometry (Table 2) with all
amino acid residues in the allowed region of the Rama-
chandran plot (96.1% in the favored region and 0% out-
liers). Initial Fo–Fc maps showed clear electron density of
the inhibitor in the active site of NA (Figure 2A). The two
substituents of the inhibitor's pyrrolidine ring were buried
inside the active site cavity (dihedral angle C6-C5-N5-C13
at the atropisomeric center −112°) with no indication of al-
ternative conformers with rotation about the C8-N bond.
The Fo–Fc maps revealed very good electron density for the
propyl group involving C9, C10 and C11, but the other
propyl group involving C12, C13 and C14 was disordered
(Figure 2), showing two tracks of weak electron density.
We tried to refine this branch with split occupancy, but the
electron density after refinement was not continuous. This
result suggested that this branch adopted additional confor-
mations and that each of the two tracks of weak electron
density had much less than 50% occupancy. At this point,
we decided to model this branch in one partially occupied
conformation rather than all of the possible conformations.
Potential interactions between inhibitor 2 and N9 NA
were assessed using Chimera [28]. In addition, potential
hydrogen bonds as well as hydrophobic contacts were
identified with HBPLUS [29] (see Table 3 for the geomet-
ric criteria). Favorable hydrophobic contacts were
defined as non-bonded contacts between two carbon
atoms at a distance of ≤4 Å [30].
Structural studies of complexes between several ben-
zoic acid leads and type B NA showed that these inhibi-
tors were bound in the active site in a similar fashion to
sialic acid [21,32], and the same is observed in the new
structure (Figure 3). The carboxylate group of the inhibi-
tor interacts with the guanidinium groups of arginine
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No. Amino Acids 391
No. Glycan monomers 15
No. D-glucose molecules 4
No. Waters 458
(Statistics for the highest resolution shell are in parentheses).
*Rmerge is high in the highest resolution shell due to the high multiplicity of the
data. The Rp.i.m. is independent of the data multiplicity and shows that the data
in the highest shell have a reasonable discrepancy of 25%. Rp.i.m.is the
precision indicating Rmerge [27].
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substrate and inhibitor complexes and calculated to be
energetically important [33]. A weak hydrogen bond is
seen between Tyr406 and the carbonyl oxygen that inter-
acts with Arg292. The pyrrolidine ring interacts with
Arg152 by forming a hydrogen bond with its carbonyl
oxygen (O15). The methylene group C16 lies in the
hydrophobic pocket formed by Trp178 and Arg152. The
methylene group C17 is involved in C-H. . .O bonds with
Trp178 carbonyl O and Glu227 OE2. One of the hy-
droxyl methyl groups (O20) is hydrogen bonded to
Glu277. Atom O20 also interacts with Glu276 through
two water molecules, HOH553 and HOH612, by a chainof hydrogen bonds. The other hydroxyl methyl group
(O19) was directed toward Trp178 O and Glu119 OE2.
The one well-ordered propyl chain is anchored by hydro-
phobic contacts with Ile222, Ala246, and Arg224. The
other propyl chain that is disordered is exposed to the
solvent and therefore not contributing to binding energy
because the one interaction seen (Table 3) is of low oc-
cupancy and at the upper limit of the distances consid-
ered as significant.
Comparative analysis
The model of 2 complexed with N9 NA was compared to
sialic acid complexes with A/Tokyo/3/1967 N2 NA, PDB
ID: 2BAT [35] and A/tern/Australia/G70c/75 N9 NA,
PDB ID: 1MWE [26]. When our new structure was fitted
with CCP4's SUPERPOSE [36] using the 11 active site resi-
dues, the root mean square deviations (RMSDs) were
0.7 Å to N2 and 0.4 Å to N9. The model gave a RMSD of
1.65 Å when superposed on the complex of compound 1
with B/Lee/40 NA [21] using COOT secondary structure
matching [37]. These small RMSDs suggest that replacing
the sialic acid ligand with the inhibitor did not disturb the
orientation of the active site residues of NA. The larger de-
viation between N9 and B NAs was expected given that
there is less than 30% sequence identity. In all the above
comparisons, most of the active site residues (Asn151,
Arg152, Glu227, Arg371, Arg292 and Arg118—numbering
as in the current complex) superposed well in the two
molecules and a maximum shift of 0.2 to 0.5 Å was
observed. However, the side chain of Glu276 showed sig-
nificant conformational change in the current complex
when compared to NA-sialic acid or NA-zanamivir com-
plexes. The two oxygen atoms OE1 and OE2 of Glu227 in
the current complex moved toward the solvent and away
from the active site by 1 Å. In this position, the carboxyl
group interacted with NE of Arg224 and NH2 of His274.
Hence, Glu276 did not form the direct hydrogen bonds
with the inhibitor hydroxyl oxygen O20 analogous to those
that Glu276 formed with the glycerol side chain of sialic
acid and its transition state mimics. However, O20 of the
inhibitor was linked to Glu276 through the water mole-
cules HOH552 and HOH611. The C14 atom of the inhibi-
tor is seen to make a hydrophobic contact with Glu276
but the low occupancy of the C12-C14 chain precludes a
significant contribution to binding.
In the compound 1 complex with influenza B NA [21],
the aliphatic chain forms van der Waals contacts with the
side chains of Arg292, Asn294 and Glu275 while the hydro-
xymethyl groups interact with Glu117, Trp177 and Glu276.
The rotation of the Glu276 side chain towards Arg224
observed in our complex was noted in the other structures
where the inhibitor carries a hydrophobic side chain [21].
N1 NAs have additional flexibility compared to N9 in the
150 loop but binding of oseltamivir to wild-type N1 NA
Figure 2 Electron density of inhibitor 2 in the active site. A, 2Fo-Fc map of inhibitor contoured at 1σ shows inhibitor fitting snugly in
the active site cavity; B, 2Fo-Fc map of inhibitor and interacting amino acids of the NA.
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Glu276 relative to the ligand free enzyme [20,38] similar to
that seen in N9 NAs.
We compared the NA and inhibitor contacts with previ-
ously reported benzoic acid inhibitor-NA structures using
Chimera with the relatively stringent constraint of distance
≤3.5 Å and including both polar and hydrophobic contacts. In
the BANA 113-B NA complex [15] [39], 12 drug atom made
21 contacts ≤3.5 Å with 10 amino acids of NA. In 1-B NA
[21], 14 drug atoms make 23 contacts with 13 amino acids.
Inhibitor 2 shows a small increase to 15 drug atoms making
28 contacts with 12 amino acids. The benzene ring of 2 is
tilted by 8.9° relative to compound 1 (Figure 4), increasing the
number of contacts as was predicted in the design. However,
one branch of the 3-heptyl group makes no significant con-
tacts due to multiple conformations, which may be why the
IC50 is no better than the previous compounds (Table 1).
Inhibitor 2 did not bind to the second sialic acid bind-
ing site observed in the structure of N9 complexed with
sialic acid at low temperature [26] (PDB ID, 1MWE) or
at room temperature (PDB ID, 2CML).
Glycan structures
When compared to the structure of the N9 mutant
R292K (PDB ID, 2QWA) and the 1.4 Å resolution struc-
tures of native N9 in complex with other inhibitors (PDB
IDs, 1F8D and1F8E), our structure has four additional
sugar units in the glycan chains attached to the delta ni-
trogen atoms of Asn146 and Asn200 (N2 numbering)
(Figure 5). At site 146, we found a second NAG residue
and evidence for a β-D-mannose (BMA). At site 200, we
found two additional mannose residues. One mannose
(Man477) is bonded to the O6 oxygen of Man475G. The
second mannose (Man476H) is linked to the O3 oxygen
atom of Man475G, resulting in a GlcNAc2-Man7 struc-
ture (Figure 5B). This glycan attached to Asn200 con-
tacts 11 amino acids of the neighboring subunit whenthe tetramer is built by symmetry (Table 4 and Figure 5C).
A high-mannose glycan at Asn200 is also present in N2 (A/
Tokyo/67) NA, where it interacts with the adjacent sym-
metry-related subunit at amino acids 391–394 and 453–455
(PDB ID, 1NN2). This glycan forms part of the Mem5
monoclonal antibody epitope on the 1998 N2 NA, and its
interactions with the adjacent subunit are not disturbed by
the presence of the antibody [41], suggesting the subunit
interactions are energetically significant. In N9 there is
experimental evidence that the glycan attached to
Asn200 contributes to folding or oligomerization be-
cause the mutation N200L in N9 NA resulted in 80%
reduction in enzyme activity although the expression
level was the same as wild type [42]. In both N2 and N9
this subunit-spanning glycan is of the high mannose
type, as is the glycan at 86 in N2 [43]. N6 NA (PDB ID
1V0Z) crystallized with the tetramer as the asymmetric
unit, so there is direct evidence for the inter-subunit
interaction of the glycan attached to Asn200 in N6 NA.
N1 NAs do not have a predicted glycosylation site at
200, but a study of N1 NA assembly suggested that tet-
ramerization requires high-mannose glycans. When all
the glycans were processed to complex structures then
the resulting dimers and monomers did not assemble
into tetramers [44]. The PDB structures of N1 NA have
no density for sugar residues, so it is not known if one
of the other glycans is a high-mannose structure that
spans the subunit interface in the same way as the gly-
can at Asn200 in N9, N2 and N6.
Glucose molecules
We used 49% (w/v) glucose as cryoprotectant, and we
observed four glucose molecules bound with greater than
50% occupancy in the structure of the inhibitor complex
(Figure 4A). The glucose molecules are in a mix of alpha
and beta configurations about the anomeric carbon atom.
The O3 oxygen atom of Glc487 interacts with the ND2
Table 3 Contacts observed between inhibitor 2 and N9 NA; 3LV is the residue name assigned to the inhibitor by the
PDB and 488 is the residue number of the inhibitor
Inhibitor atom N9 atom distance (Å) Angle(D-A-AA)°
Potential hydrogen bonds1
3LV488-O1 Arg118-NH1 2.84 117.3
3LV488-O1 Arg371-NH1 2.86 112.8
3LV488-O2 Arg292-NH1 3.34 97.1
3LV488-O2 Arg292-NH2 3.25 101.2
3LV488-O2 Arg371-NH2 2.84 124.9
3LV488-O2 HOH-747 2.85
HOH-747 3.25 Asn347 OD1
3LV488-O15 Arg152- NH1 2.54 145.9
3LV488-O20 HOH-612 2.72
HOH-612 2.82, 3.16 Glu227 OE2, Thr225 O
Van der Waals contacts2 (≤4.0 Å)









3LV488-C2 Tyr406-OH 2.80 136.4
3LV488-O2 Tyr406-OH 3.32 123.93
Arg371-CZ 3.76 38.3
Arg371-NH1 3.82 96.2
3LV488-C3 Tyr406-OH 3.19 161.8









3LV488-C10 Ile222-CD1 3.63 122.8
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Table 3 Contacts observed between inhibitor 2 and N9 NA; 3LV is the residue name assigned to the inhibitor by the
PDB and 488 is the residue number of the inhibitor (Continued)
Arg224-NH2 3.81 63.4
HOH-945 2.82 —
3LV488-C14 Arg292-NH24 3.50 140.0









3LV488-C17 Trp178-O 3.43 139.6
Glu227-OE2 3.62 135.8
3LV488-C19 Trp178-O 3.19 167.7
Glu119-CD 3.88 85.8












Water bridge – inhibitor – Glu276
3LV488-O20 HOH-612 2.72
612-HOH 553-HOH 2.64
553-HOH Glu276-OE1 2.82 142.2
Glu276 interactions
Glu276-OE1 Arg224-NE 2.72 114.2
Glu276-OE2 Arg224-NE 3.50 83.2
Glu276-OE2 Arg224-NH2 2.81 115.9
Glu276-OE2 His274-NE2 2.73 119.7
1Potential hydrogen bonds were identified using HBPLUS [29]. Potential hydrogen bonds were interactions between donor and acceptor atoms that met the following geometric
requirements: (i) a donor acceptor distance (D-A)< 3.5 Å and a hydrogen acceptor distance (H-A)< 2.5 Å and (ii) a donor-acceptor-acceptor antecedent angle (D-A-AA), of> 90° [31].
2Favorable hydrophobic contacts were defined as non-bonded contacts between two carbon atoms at a distance of ≤4 Å [28].
3Freely rotating hydroxyl hydrogen atoms had the potential to form hydrogen bonds with two alternative acceptor atoms. Only the more probable acceptor atom
at the shorter distance from the hydrogen atom was reported by HBPLUS.
4There were several conformations of the propyl chain C12-C14. We used the best, but it is of low occupancy so the interactions involving C14 contribute very little.
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and O1 of Glc486 forms hydrogen bonds with NE2 of
Gln315 and ND2 of Asn338 respectively.Conclusions
Our aim in designing inhibitor 2 was to extend the substitu-
ent at C4, corresponding to C6 of sialic acid, to (i) increase
Figure 3 Interactions between compound 2 and NA. Ligplot + [34] diagram showing interactions.
Figure 4 Bound configurations of Compound 1 (PDB ID 1B9V;
cyan) compared to compound 2 (magenta). The proteins of the
complex structures were aligned using DaliLite [40]. The view is in
the plane of the benzene ring of 1, showing that the benzene ring
of 2 is slightly rotated as well as tilted 8.9° compared to 1.
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zene ring to tilt to maximize these interactions while retain-
ing the interactions of the carboxylate and the pyrolidinone
substituents. The crystal structure at 1.55 Å shows that we
were partially successful in that the ring in 2 is tilted relative
to compound 1 (Figure 4) and the overall number of contacts
is increased. The IC50 did not decrease, and the reason be-
came clear when we solved the crystal structure. The second
propyl group is not making any contacts but is freely waving
above the surface of the NA. Future design efforts will in-
clude unequal branches that may be accommodated in the
C6-subsite.
The N9 NA that was crystallized for this experiment
was purified from virus grown in embryonated chicken
eggs, so it contains a full complement of vertebrate pro-
cessed N-linked glycans, in contrast to NA expressed in
insect cells which has truncated glycan structures. We
therefore refined the glycans as far as we could see elec-
tron density. Most glycans are flexible and only the first
few sugars are seen, but the glycan attached to Asn200 is
well resolved due to interaction with the adjacentsubunit and is seen to contain GlcNAc2Man7. Mutation
data suggests this glycan plays a role in stabilizing the
NA tetramer, which is a significant property because, for
Figure 5 A. Carbohydrates in the N9-compound 2 model at 1.55 Å resolution. Carbon atoms are green for N9 NA and the N-linked glycans
attached at positions 86, 146 and 200 that are in common with other structures. Mannose residues not previously seen in N9 structures (blue) and
the four glucose molecules from the cryoprotectant (yellow) are shown. Compound 2 is colored gray. B. Electron density (2Fo-Fc at 1σ) for the
glycan at Asn200. Also shown is the cartoon of the glycan structure using standard Consortium for Functional Glycomics symbols (green circle,
mannose; blue square, N-acetylglucosamine) made with Glycan Builder [45]. C. Interaction of the glycan attached to Asn200 (green) with the
neighboring subunit (gray) built by applying crystallographic symmetry.
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mer has enzymatic activity.
Materials and methods
Inhibitor synthesis
The synthesis, purification and evaluation of the in vitro
inhibitory activity of 2 {4-[2,2-bis(hydroxymethyl)-5-oxo-
pyrrolidin-1-yl]-3-[(dipropylamino)methyl]benzoic acid}
will be described elsewhere [23].
Protein preparation and crystallization
The reassortant virus A/NWS/33H-A/tern/Australia/G70C/
75N (H1N9) was grown and purified as previously described
[25]. The purified virus was digested with Pronase (Sigma) at
a concentration of 6 mg/ml at 37 C for 16 hours. The cores
were removed by centrifugation, and the released heads were
pooled, concentrated, and purified by gel filtration using
FPLC [41]. The purified protein was concentrated to 10 mg/
ml. Single crystals of N9 NA were grown by vapor diffusionusing the hanging drop method containing equal volumes of
N9 and the reservoir solution of 1.9 M potassium phosphate
buffer pH 6.9 [8].
Inhibitor soaking, cryoprotection and X-ray data collection
The successful flash cooling of large (0.2−0.4 mm per edge)
cubic crystals in liquid nitrogen required serial equilibration
by vapor diffusion. The estimated osmolality for 1.9 MK-
phosphate buffer (pH 6.9) in the reservoir solution was
matched to that of glucose using standard tables [46,47].
Crystals were placed over wells with 200 mM K-phosphate
buffer (pH 6.9) containing 45 g/100 ml (45%w/v) glucose for
6 hours to two days and then placed over a well with 46%
glucose. This procedure was repeated until the crystals were
over wells that contained 49% glucose. After the final equili-
bration, the crystals were soaked in 49% glucose and
200 mM K-phosphate with 25 mM inhibitor for 5 minutes
before they were mounted in a rayon cryoloop and vitrified
at 100 K in a nitrogen cold-stream.
Table 4 Contacts <3.5 Å between the high mannose
glycan at Asn200 and the adjacent subunit built as a
symmetry-related monomer
Sugar Sugar atom Amino acid Atom Distance (Å)
NAG469A O5 G454 CA 3.39
Q455 N 3.35
C6 L453 O 3.43
O6 Q455 CG 3.25
NAG 470B O3 G394 N 2.96
C3 G394 O 3.16
BMA 471 C O2 G394 CA 3.21
MAN 472D O3 R364 NH2 3.02
C3 E375 OE1 3.39
O3 E375 OE2 2.58
O4 E375 OE1 2.75
MAN 473E O5 R364 NH2 3.15
O6 K389 NZ 2.82
O6 D330 OD2 2.54
MAN 473 F O2 N329 OD1 3.10
O3 D330 N 2.93
O3 N329 OD1 2.74
O3 N329 CA 2.99
O4 R327 NH2 3.11
O6 I366 O 2.75
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http://www.biomedcentral.com/1472-6807/12/7X-ray data were collected at 100 K at SSRL beam line
7–1 on an ADSC Quantum 315 CCD detector using
monochromatic radiation with a wavelength of 0.9537 Å.
The X-ray data were collected at distances of 300 and
220 mm with oscillation angles of 0.5° and 0.35° respect-
ively and with 2 s exposures at both distances.
The X-ray data were indexed and integrated with XDS
[48]. The integrated intensities were scaled and merged
with the CCP4 [49] program SCALA [50] and converted
to structure factors with TRUNCATE [51].
Structure determination and analysis
The structure was solved by molecular substitution. The
1.7 Å crystal structure of the R292K mutant of tern N9
influenza virus NA [24] (2QWA) without the glycans or
solvent molecules was used as the starting model in rigid
body and coordinate refinement in REFMAC [52]. Re-
finement was continued using PHENIX [53] together
with iterative rounds of model rebuilding using the mo-
lecular graphic package COOT [37]. The PRODRG web-
server [54] was used to build the initial coordinates and
stereochemical restraints of inhibitor 2. The restraints
for three β-D-mannose monomers (BMA) were taken
from the REFMAC library [34]. Riding hydrogen atoms
were added with the program REDUCE [55].The structure was analyzed with HBPLUS [29] and
Chimera [28]. The figures were made using PyMOL
(Schrödinger LLC) and Liglot+ [56].
Accession codes
The atomic coordinates and structure factors were
deposited in the protein data bank under accession code
4DGR for the inhibitor complex.
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